Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics.
作者信息
Hafner Marc, Niepel Mario, Sorger Peter K
机构信息
HMS LINCS Center, Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Nat Biotechnol. 2017 Jun 7;35(6):500-502. doi: 10.1038/nbt.3882.
Abstract
摘要
相似文献
1
Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics.
Nat Biotechnol. 2017 Jun 7;35(6):500-502. doi: 10.1038/nbt.3882.
2
Pharmacogenomic agreement between two cancer cell line data sets.
Nature. 2015 Dec 3;528(7580):84-7. doi: 10.1038/nature15736. Epub 2015 Nov 16.
3
Pharmacogenetics and pharmacogenomics: a clinical reality.
Ann Clin Biochem. 2011 Sep;48(Pt 5):410-7. doi: 10.1258/acb.2011.011084. Epub 2011 Jul 6.
4
Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies.
Oncotarget. 2016 Aug 9;7(32):51619-51625. doi: 10.18632/oncotarget.10010.
5
Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
Drug Metab Pers Ther. 2016 Mar;31(1):25-34. doi: 10.1515/dmpt-2015-0042.
6
Primer on medical genomics. Part XII: Pharmacogenomics--general principles with cancer as a model.
Mayo Clin Proc. 2004 Mar;79(3):376-84. doi: 10.4065/79.3.376.
7
Cancer pharmacogenomics: do cancer cell lines have the right stuff?
Pharmacogenomics. 2010 Aug;11(8):1035-7. doi: 10.2217/pgs.10.107.
8
Pharmacogenetics and pharmacogenomics as new tools to optimise cancer chemotherapy.
J Chemother. 2004 Nov;16 Suppl 4:22-4. doi: 10.1179/joc.2004.16.Supplement-1.22.
9
Somatic pharmacogenomics in cancer.
Pharmacogenomics J. 2008 Oct;8(5):305-14. doi: 10.1038/tpj.2008.8. Epub 2008 Aug 5.
10
Evaluating the consistency of large-scale pharmacogenomic studies.
Brief Bioinform. 2019 Sep 27;20(5):1734-1753. doi: 10.1093/bib/bby046.
引用本文的文献
1
Unsupervised cell line embedding using pairwise drug response correlation.
Comput Struct Biotechnol J. 2025 Jun 11;27:2566-2573. doi: 10.1016/j.csbj.2025.06.018. eCollection 2025.
2
Comprehensive Analysis of Drug Response using the FLICK Assay.
J Vis Exp. 2025 Jun 6(220). doi: 10.3791/67768.
3
Optimizing drug synergy prediction through categorical embeddings in deep neural networks.
Biol Methods Protoc. 2025 Apr 28;10(1):bpaf033. doi: 10.1093/biomethods/bpaf033. eCollection 2025.
4
Estimating treatment sensitivity in synthetic and in vitro tumors using a random differential equation model.
NPJ Syst Biol Appl. 2025 May 23;11(1):54. doi: 10.1038/s41540-025-00530-0.
5
Application of drug-induced growth rate inhibition and intracellular drug exposures for comprehensive evaluation of cellular drug sensitivity.
Sci Rep. 2025 Feb 11;15(1):5064. doi: 10.1038/s41598-025-86919-7.
6
A precision oncology-focused deep learning framework for personalized selection of cancer therapy.
bioRxiv. 2024 Dec 16:2024.12.12.628190. doi: 10.1101/2024.12.12.628190.
7
Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors.
Genome Biol. 2024 Dec 2;25(1):301. doi: 10.1186/s13059-024-03438-w.
8
Development of an automated 3D high content cell screening platform for organoid phenotyping.
SLAS Discov. 2024 Oct;29(7):100182. doi: 10.1016/j.slasd.2024.100182. Epub 2024 Sep 6.
9
Chemogenomics for NR1 nuclear hormone receptors.
Nat Commun. 2024 Jun 18;15(1):5201. doi: 10.1038/s41467-024-49493-6.
10
Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries.
Sci Data. 2024 Feb 6;11(1):171. doi: 10.1038/s41597-024-03018-4.
本文引用的文献
1
Designing Drug-Response Experiments and Quantifying their Results.
Curr Protoc Chem Biol. 2017 Jun 19;9(2):96-116. doi: 10.1002/cpch.19.
2
Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells.
Curr Protoc Chem Biol. 2017 Jun 19;9(2):55-74. doi: 10.1002/cpch.21.
3
Reproducible pharmacogenomic profiling of cancer cell line panels.
Nature. 2016 May 19;533(7603):333-7. doi: 10.1038/nature17987.
4
An unbiased metric of antiproliferative drug effect in vitro.
Nat Methods. 2016 Jun;13(6):497-500. doi: 10.1038/nmeth.3852. Epub 2016 May 2.
5
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs.
Nat Methods. 2016 Jun;13(6):521-7. doi: 10.1038/nmeth.3853. Epub 2016 May 2.
6
Cell Death and Cancer Therapy: Don't Forget to Kill the Cancer Cell!
Clin Cancer Res. 2015 Nov 15;21(22):5015-20. doi: 10.1158/1078-0432.CCR-15-1204.
7
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.
Cancer Discov. 2015 Nov;5(11):1210-23. doi: 10.1158/2159-8290.CD-15-0235. Epub 2015 Oct 19.
8
Inconsistency in large pharmacogenomic studies.
Nature. 2013 Dec 19;504(7480):389-93. doi: 10.1038/nature12831. Epub 2013 Nov 27.
9
Metrics other than potency reveal systematic variation in responses to cancer drugs.
Nat Chem Biol. 2013 Nov;9(11):708-14. doi: 10.1038/nchembio.1337. Epub 2013 Sep 8.
10
Cancer genome landscapes.
Science. 2013 Mar 29;339(6127):1546-58. doi: 10.1126/science.1235122.
Zotero 插件